Healthcare Industry News: schizophrenia
News Release - August 29, 2008
ARYx Therapeutics Appoints Amgen Executive to Board of DirectorsDavid Beier, Amgen Senior Vice President, Joins Board of Fremont Biotechnology Company
FREMONT, Calif.--(HSMN NewsFeed)--ARYx Therapeutics, Inc. (NASDAQ:ARYX ) today announced the appointment of David Beier to its board of directors. Mr. Beier is a veteran of the biotechnology industry and has been instrumental in the development of United States public policy impacting biotechnology companies, having served in both the industry and the Clinton Administration.
“I am very pleased to welcome David to our board of directors,” said Dr. Paul Goddard, ARYx chairman and chief executive officer. “As each of our products moves through development, someone with David’s extraordinary experience will be invaluable in helping to position them in the marketplace. His expertise in health economics, reimbursement and outcomes research will aid ARYx enormously. In addition, someone who has equal experience in the management of biotech companies and the challenges of international politics can undoubtedly make invaluable contributions.”
Mr. Beier is currently senior vice president of global government and corporate affairs for Amgen Inc, one of the world’s leading biotechnology companies. Mr. Beier is responsible for global health care issues, health economics and outcomes research, corporate communications and philanthropy, and government affairs at the United States federal and state levels as well as with international governmental entities and organizations. Prior to joining Amgen, he was a partner in the international law firm of Hogan & Hartson, and was vice president of government affairs and public policy for Genentech Inc. Mr. Beier’s extensive government experience includes serving as chief domestic policy advisor to Vice President Al Gore and as staff counsel in the U.S. House of Representatives. He received a B.A. from Colgate University and his J.D. from Albany Law School.
“It is very impressive to me that ARYx began focusing on making safer drugs long before the Congress and others learned what they know today. Biotechnology exists to improve people’s lives and the ARYx approach uniquely balances efficacy with safety,” stated Mr. Beier. “I look forward to making whatever contributions I can on behalf of the Company and its shareholders.”
About ARYx Therapeutics, Inc.
ARYx Therapeutics is a biopharmaceutical company focused on developing a portfolio of internally discovered products designed to eliminate known safety issues associated with well-established, commercially successful drugs. ARYx uses its RetroMetabolic Drug Design(TM) technology to design structurally unique molecules that retain the efficacy of these original drugs but are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these compounds. ARYx currently has four products in clinical trials: an oral anticoagulant agent for patients at risk for the formation of dangerous blood clots, ATI-5923; an oral anti-arrhythmic agent for the treatment of atrial fibrillation, ATI-2042; a prokinetic agent for the treatment of various gastrointestinal disorders, ATI-7505; and, an agent for the treatment of schizophrenia and other psychiatric disorders, ATI-9242. Please visit our web site at www.aryx.com for additional information.
Source: ARYx Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.